$BGNE with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $BGNE after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 66.67%.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.58USD
−883.77 MUSD
2.46 BUSD
908.31 M
About BEIGENE, LTD.
Sector
CEO
John V. Oyler
Headquarters
George Town
Website
Employees (FY)
10 K
Founded
2010
FIGI
BBG00YJV1CB6
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
$BGNE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BGNE after a Negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 80%.
$BGNE with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BGNE after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 100%.
#6160 pull-back and hits support line $213.6 Hi Everybody
#6160 pull-back and hits support line $213.6, expects to test the BLUE LINES, and stops if closes below the RED line.
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA BGNE: BeiGene, Ltd.
2021-07-29 20:00:00
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
BGNE short above 260$, target price 161$, about Mar 9, 2021.BGNE short above 260$, target price 161$, about Mar 9, 2021.
Similar pattern of Aug 8, 2018.
Wait BGNE price reached 161$, start building long position.
It's not a good idea holding BGNE under 270$~260$
Long stop-Loss price : 259$
Short stop-loss price : 284$
BGNE: Long strategy after gap overlapWe will trade long in the range $140 - 150 amid to gap overlap. Target will be $190 / 200. (+30% potentially)
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BEIGF is featured.
Frequently Asked Questions
The current price of BEIGF is 12.58 USD — it has increased by 14.36% in the past 24 hours. Watch BeiGene, Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange BeiGene, Ltd. stocks are traded under the ticker BEIGF.
We've gathered analysts' opinions on BeiGene, Ltd. future price: according to them, BEIGF price has a max estimate of 26.61 USD and a min estimate of 11.71 USD. Watch BEIGF chart and read a more detailed BeiGene, Ltd. stock forecast: see what analysts think of BeiGene, Ltd. and suggest that you do with its stocks.
BEIGF reached its all-time high on Aug 18, 2023 with the price of 16.78 USD, and its all-time low was 11.00 USD and was reached on Apr 12, 2024. View more price dynamics on BEIGF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BEIGF stock is 12.56% volatile and has beta coefficient of 1.26. Track BeiGene, Ltd. stock price on the chart and check out the list of the most volatile stocks — is BeiGene, Ltd. there?
Today BeiGene, Ltd. has the market capitalization of 18.05 B, it has increased by 3.26% over the last week.
Yes, you can track BeiGene, Ltd. financials in yearly and quarterly reports right on TradingView.
BeiGene, Ltd. is going to release the next earnings report on Aug 23, 2024. Keep track of upcoming events with our Earnings Calendar.
BEIGF earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.24 USD resulting in a 22.19% surprise. The estimated earnings for the next quarter are −0.17 USD per share. See more details about BeiGene, Ltd. earnings.
BeiGene, Ltd. revenue for the last quarter amounts to 750.66 M USD despite the estimated figure of 664.15 M USD. In the next quarter revenue is expected to reach 783.47 M USD.
BEIGF net income for the last quarter is −250.92 M USD, while the quarter before that showed −367.72 M USD of net income which accounts for 31.76% change. Track more BeiGene, Ltd. financial stats to get the full picture.
No, BEIGF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 21, 2024, the company has 10.00 K employees. See our rating of the largest employees — is BeiGene, Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BeiGene, Ltd. EBITDA is −1.00 B USD, and current EBITDA margin is −45.55%. See more stats in BeiGene, Ltd. financial statements.
Like other stocks, BEIGF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BeiGene, Ltd. stock right from TradingView charts — choose your broker and connect to your account.